Yükleniyor... / Loading...
This study investigates how genes relate to the response to Pioglitazone, a thiazolidinedione diabetes drug (pharmacogenomics). It enrolled participants aged 35-64 with a body mass index between 25 and 40. This study had no assigned phase and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Age 35-64 * BMI: ≥ 25 and ≤ 40 Exclusion Criteria: * Pregnancy as determined by urine pregnancy test Breast-feeding, or planning to become pregnant during the study * Physical dimensions exceeding the limits of any equipment used * Stage III or greater congestive heart failure * Symptomatic peripheral vascular disease * Stroke * Severe hypertension (\>170/100 mmHg) * Anemia (Hgb and Hct \< normal reference range) * Receiving treatment for thyroid, pituitary, kidney or liver disease (except controlled thyroid hormone replacement) * History of diabetes (as told by doctor, or taking diabetic medications Fasting glucose value diagnostic for diabetes 2-h oral glucose tolerance test diagnostic for diabetes * Rheumatoid arthritis * History of wrist, hip or leg fracture after the age of 45 * History of kidney stones * Medications that the investigator judges will make interpretation of the results difficult or increase the risk of participation (e.g. anticoagulants) * Any disease or condition that the investigator judges will affect bone metabolism or make interpretation of the results difficult or increase the risk of participation (e.g. anemia, cardiac decompensation, intolerance to pioglitazone, lidocaine, or other agents used)